SynthesisThe Cochrane database of systematic reviews2010
Growth hormone for in vitro fertilization.
Synthesis in The Cochrane database of systematic reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 6 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis.Reproductive biology and endocrinology : RB&E · 2023Pooled it
- The effect of growth hormone supplementation in poor ovarian responders undergoing IVF or ICSI: a meta-analysis of randomized controlled trials.Reproductive biology and endocrinology : RB&E · 2020Pooled it
- Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.The Cochrane database of systematic reviews · 2019Pooled it
- Assisted reproductive technology: an overview of Cochrane Reviews.The Cochrane database of systematic reviews · 2018Pooled it
- Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.The Cochrane database of systematic reviews · 2017Pooled it
- Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.The Cochrane database of systematic reviews · 2013Pooled it
- Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial.Human reproduction (Oxford, England) · 2025Trial
- Does growth hormone supplementation improve oocyte competence and IVF outcomes in patients with poor embryonic development? A randomized controlled trial.BMC pregnancy and childbirth · 2020Trial
- [Growth hormone and fertility: molecular mechanisms and experience of adjuvant therapy in reproductology].Problemy endokrinologii · 2026Review
- Considerations of Fertility in Elite Sportswomen: A Narrative Review.BJOG : an international journal of obstetrics and gynaecology · 2026Review
- Impact of Endocrine Disruptors on the Genitourinary Tract.Journal of xenobiotics · 2024Review
- An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management.Journal of clinical medicine · 2024Review
- Genomic analysis of Tibetan ground tits identifies molecular adaptations associated with cooperative breeding.Current zoology · 2023Article
- Impact of Follicle Stimulating Hormone Receptor (FSHR) Polymorphism on the Efficiency of Co-Treatment with Growth Hormone in a Group of Infertile Women from Romania.Diagnostics (Basel, Switzerland) · 2022Article
- The Clinical Application of Growth Hormone and Its Biological and Molecular Mechanisms in Assisted Reproduction.International journal of molecular sciences · 2022Review
- Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging.Frontiers in endocrinology · 2022Review
- Growth hormone in fertility and infertility: Mechanisms of action and clinical applications.Frontiers in endocrinology · 2022Review
- Role of the GH-IGF1 axis on the hypothalamus-pituitary-testicular axis function: lessons from Laron syndrome.Endocrine connections · 2021Article
- Growth hormone supplementation during ovarian stimulation improves oocyte and embryo outcomes in IVF/PGT-A cycles of women who are not poor responders.Journal of assisted reproduction and genetics · 2021Article
- Follicular GH and IGF1 Levels Are Associated With Oocyte Cohort Quality: A Pilot Study.Frontiers in endocrinology · 2021Article
Corrections and comments
- Updated by
- Update of
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn an effort to improve outcomes of in-vitro fertilisation cycles the use of growth hormone has been considered. Improving the outcomes of in-vitro fertilisation is especially important for subfertile women who are considered 'poor responders'.
objectivesTo assess the effectiveness of adjuvant growth hormone in in-vitro fertilisation protocols. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Groups trials register (June 2009), the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 2, 2009), MEDLINE (1966 to June 2009), EMBASE (1988 to June 2009) and Biological Abstracts (1969 to June 2009). SELECTION CRITERIA: All randomised controlled trials were included if they addressed the research question and provided outcome data for intervention and control participants. DATA COLLECTION AND ANALYSIS: Assessment of trial risk of bias and extraction of relevant data was performed independently by two reviewers. MAIN
resultsTen studies (440 subfertile couples) were included. Results of the meta-analysis demonstrated no difference in outcome measures and adverse events in the routine use of adjuvant growth hormone in in-vitro fertilisation protocols. However, meta-analysis demonstrated a statistically significant difference in both live birth rates and pregnancy rates favouring the use of adjuvant growth hormone in in-vitro fertilisation protocols in women who are considered poor responders without increasing adverse events, OR 5.39, 95% CI 1.89 to 15.35 and OR 3.28, 95% CI 1.74 to 6.20 respectively. AUTHORS'
conclusionsAlthough the use of growth hormone in poor responders has been found to show a significant improvement in live birth rates, we were unable to identify which sub-group of poor responders would benefit the most from adjuvant growth hormone. The result needs to be interpreted with caution, the included trials were few in number and small sample size. Therefore, before recommending growth hormone adjuvant in in-vitro fertilisation further research is necessary to fully define its role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.